Paclitaxel poliglumex (PPX, CT-2103): macromolecular medicine for advanced non-small-cell lung cancer

References

• Ranson M, Davidson N, Nicolson M et al. Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer. J. Natl Cancer Inst.92, 1074–1080 (2000).
   PubMed Web of Science ®Google Scholar
• Roszkowski K, Pluzanska A, Krzakowski M et al. A multicenter, randomized, Phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC). Lung Cancer27, 145–157 (2000).
   PubMed Web of Science ®Google Scholar
• Anderson H, Hopwood P, Stephens RJ et al. Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer – a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer. Br. J. Cancer83, 447–453 (2000).
   PubMed Web of Science ®Google Scholar
• Fu JB, Kau TY, Severson RK, Kalemkerian GP. Lung cancer in women: analysis of the national Surveillance, Epidemiology, and End Results database. Chest127, 768–777 (2005).
   PubMed Web of Science ®Google Scholar
• Jemal A, Murray T, Ward E et al. Cancer statistics, 2005. CA Cancer J. Clin.55, 10–30 (2005).
   PubMed Web of Science ®Google Scholar
• Pfister DG, Johnson DH, Azzoli CG et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J. Clin. Oncol.22, 330–353 (2004).
   PubMed Web of Science ®Google Scholar
• Ettinger D, Johnson B. Update: NCCN small cell and non-small cell lung cancer Clinical Practice Guidelines. J. Natl Compr. Canc. Netw.3(Suppl. 1), S17–S21 (2005).
   PubMedGoogle Scholar
• Schiller JH, Harrington D, Belani CP et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N. Engl. J. Med.346, 92–98 (2002).
   PubMed Web of Science ®Google Scholar
• Fossella F, Pereira JR, von Pawel J et al. Randomized, multinational, Phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J. Clin. Oncol.21, 3016–3024 (2003).
   PubMed Web of Science ®Google Scholar
• Smit EF, van Meerbeeck JP, Lianes P et al. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a Phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group – EORTC 08975. J. Clin. Oncol.21, 3909–3917 (2003).
   PubMed Web of Science ®Google Scholar
• Georgoulias V, Papadakis E, Alexopoulos A et al. Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial. Lancet357, 1478–1484 (2001).
   PubMed Web of Science ®Google Scholar
• Gridelli C, Gallo C, Shepherd FA et al. Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a Phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol.21, 3025–3034 (2003).
   PubMed Web of Science ®Google Scholar
• Oken MM, Creech RH, Tormey DC et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am. J. Clin. Oncol.5, 649–655 (1982).
   PubMed Web of Science ®Google Scholar
• Gridelli C, Ardizzoni A, Le Chevalier T et al. Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel. Ann. Oncol.15, 419–426 (2004).
   PubMed Web of Science ®Google Scholar
• Hensing T, Cella D Yount S. The impact of ECOG performance status on quality of life symptoms in patients with advanced lung cancer. J. Clin. Oncol.23, 8099 (2005).
   Google Scholar
• Buccheri G, Ferrigno D, Tamburini M. Karnofsky and ECOG performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution. Eur. J. Cancer32A, 1135–1141 (1996).
   PubMed Web of Science ®Google Scholar
• Radzikowska E, Glaz P, Roszkowski K. Lung cancer in women: age, smoking, histology, performance status, stage, initial treatment and survival. Population-based study of 20 561 cases. Ann. Oncol.13, 1087–1093 (2002).
   PubMed Web of Science ®Google Scholar
• Massaro D, Massaro GD. Estrogen regulates pulmonary alveolar formation, loss, and regeneration in mice. Am. J. Physiol. Lung Cell Mol. Physiol.287, L1154–L1159 (2004).
   PubMed Web of Science ®Google Scholar
• Massaro D, Massaro GD. Estrogen receptor regulation of pulmonary alveolar dimensions: alveolar sexual dimorphism in mice. Am. J. Physiol. Lung Cell Mol. Physiol.290(5), L866–L870 (2005).
   Google Scholar
• Wu CT, Chang YL, Shih JY, Lee YC. The significance of estrogen receptor β in 301 surgically treated non-small cell lung cancers. J. Thorac. Cardiovasc. Surg.130, 979–986 (2005).
   PubMed Web of Science ®Google Scholar
• Stabile LP, Davis AL, Gubish CT et al. Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor α and β and show biological responses to estrogen. Cancer Res.62, 2141–2150 (2002).
   PubMed Web of Science ®Google Scholar
• Liu Y, Inoue M, Sobue T, Tsugane S. Reproductive factors, hormone use and the risk of lung cancer among middle-aged never-smoking Japanese women: a large-scale population-based cohort study. Int. J. Cancer117, 662–666 (2005).
   PubMed Web of Science ®Google Scholar
• Oton AB, Belani C, Cai C et al. Comparison of survival for non-small cell lung cancer (NSCLC) between premenopausal and postmenopausal women: An analysis of the National Surveillance, Epidemiology and End Results (SEER) Database. J. Clin. Oncol.24, 7038 (2006).
   Google Scholar
• Ganti AK, Sahmoun AE, Panwalkar AW, Tendulkar KK, Potti A. Hormone replacement therapy is associated with decreased survival in women with lung cancer. J. Clin. Oncol.24, 59–63 (2006).
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med.353, 123–132 (2005).
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Dancey J, Ramlau R et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J. Clin. Oncol.18, 2095–2103 (2000).
   PubMed Web of Science ®Google Scholar
• Hanna N, Shepherd FA, Fossella FV et al. Randomized Phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J. Clin. Oncol.22, 1589–1597 (2004).
   PubMed Web of Science ®Google Scholar
• Barlesi F, Jacot W, Astoul P, Pujol JL. Second-line treatment for advanced non-small cell lung cancer: a systematic review. Lung Cancer51, 159–172 (2006).
   PubMed Web of Science ®Google Scholar
• Singer JW, Shaffer S, Baker B et al. Paclitaxel poliglumex (XYOTAX; CT-2103): an intracellularly targeted taxane. Anticancer Drugs16, 243–254 (2005).
   PubMed Web of Science ®Google Scholar
• Gueritte-Voegelein F, Guenard D, Lavelle F, Le Goff MT, Mangatal L, Potier P. Relationships between the structure of taxol analogues and their antimitotic activity. J. Med. Chem.34, 992–998 (1991).
   PubMed Web of Science ®Google Scholar
• Bernareggi F, Oldham B, Baker M, Besman JW, Singer A. XYOTAX™ (paclitaxel poliglumex, PPX): tumor accumulation and prolonged exposure to paclitaxel. Presented at: 11th World Congress on Lung Cancer. Barcelona, Spain (2005).
   Google Scholar
• Gerlowski LE, Jain RK. Microvascular permeability of normal and neoplastic tissues. Microvasc. Res.31, 288–305 (1986).
   PubMed Web of Science ®Google Scholar
• Roberts WG, Palade GE. Neovasculature induced by vascular endothelial growth factor is fenestrated. Cancer Res.57, 765–772 (1997).
   PubMed Web of Science ®Google Scholar
• Greish K, Fang J, Inutsuka T, Nagamitsu A, Maeda H. Macromolecular therapeutics: advantages and prospects with special emphasis on solid tumour targeting. Clin. Pharmacokinet.42, 1089–1105 (2003).
   PubMed Web of Science ®Google Scholar
• Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res.46, 6387–6392 (1986).
   PubMed Web of Science ®Google Scholar
• Li C, Newman RA, Wu QP et al. Biodistribution of paclitaxel and poly(L-glutamic acid)-paclitaxel conjugate in mice with ovarian OCa-1 tumor. Cancer Chemother. Pharmacol.46, 416–422 (2000).
   PubMed Web of Science ®Google Scholar
• Shaffer SA, Baker-Lee C, Kennedy J et al.In vitro and in vivo metabolism of paclitaxel poliglumex: identification of metabolites and active proteases. Cancer Chemother. Pharmacol. (2006).
   PubMedGoogle Scholar
• Yan S, Sloane BF. Molecular regulation of human cathepsin B: implication in pathologies. Biol. Chem.384, 845–854 (2003).
   PubMed Web of Science ®Google Scholar
• Podgorski I, Sloane BF. Cathepsin B and its role(s) in cancer progression. Biochem. Soc. Symp.70, 263–276 (2003).
   Google Scholar
• Rochefort H, Capony F, Augereau P et al. The estrogen-regulated 52K-cathepsin-D in breast cancer: from biology to clinical applications. Int. J. Rad. Appl. Instrum. B14, 377–384 (1987).
   PubMedGoogle Scholar
• Gallagher LJ, Sloane BF. Effect of estrogen on lysosomal enzyme activities in rat heart. Proc. Soc. Exp. Biol. Med.177, 428–433 (1984).
   PubMed Web of Science ®Google Scholar
• Westley BR, May FE. Oestrogen regulates cathepsin D mRNA levels in oestrogen responsive human breast cancer cells. Nucleic Acids Res.15, 3773–3786 (1987).
   PubMed Web of Science ®Google Scholar
• Kremer M, Judd J, Rifkin B, Auszmann J, Oursler MJ. Estrogen modulation of osteoclast lysosomal enzyme secretion. J. Cell. Biochem.57, 271–279 (1995).
   PubMed Web of Science ®Google Scholar
• Balan KV, Hollis VW, Eckberg WR et al. Cathepsin B and complement C3 are major comigrants in the estrogen-induced peroxidase fraction of rat uterine fluid. J. Submicrosc. Cytol. Pathol.33, 221–230 (2001).
   PubMedGoogle Scholar
• Waters KM, Safe S, Gaido KW. Differential gene expression in response to methoxychlor and estradiol through ERα, ERβ, and AR in reproductive tissues of female mice. Toxicol. Sci.63, 47–56 (2001).
   PubMed Web of Science ®Google Scholar
• Di Giovine S, De Feudis P, Torriani D et al. Effect of estrogen on cathepsin B activity and antitumor efficacy of Paclitaxel Poliglumex in human tumor xenografts. Eur. J. Cancer4(Suppl.), 191 (2006).
   Google Scholar
• O’Byrne KJ. Paclitaxel poliglumex vs. docetaxel for the second-line treatment of non-small cell lung cancer (NSCLC): the STELLAR 2 Phase III study. Eur. J. Cancer3(Suppl.) (2005).
   Google Scholar
• O’Byrne KJ. Paclitaxel poliglumex vs. gemcitabine or vinorelbine for the treatment of performance status (PS) 2 patients with chemotherapy-naïve advanced non-small cell lung cancer (NSCLC): the STELLAR 4 Phase III study. Eur. J. Cancer3(Suppl.), 324 (2005).
   Google Scholar
• Langer CJ, Socinski MA, Ross H, O’Byrne KJ Paclitaxel poliglumex (PPX)/carboplatin vs paclitaxel/carboplatin for the treatment of PS2 patients with chemotherapy-naïve advanced non-small cell lung cancer (NSCLC): a Phase III study. J. Clin. Oncol.3, 7011 (2005).
   Google Scholar
• Ross H, Bonomi P, Langer C et al. Effect of gender on outcome in two randomized Phase III trials of paclitaxel poliglumex (PPX) in chemonaïve pts with advanced NSCLC and poor performance status (PS2). J. Clin. Oncol.24, 7039 (2006).
   Google Scholar
• Albain KS, Belani CP, Bonomi P, O’Byrne KJ, Schiller JH, Socinski M. PIONEER: a Phase III randomized trial of paclitaxel poliglumex versus paclitaxel in chemotherapy-naive women with advanced-stage non-small-cell lung cancer and performance status of 2. Clin. Lung Cancer7, 417–419 (2006).
   PubMed Web of Science ®Google Scholar
• Lilenbaum RC, Herndon JE II, List MA et al. Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730). J. Clin. Oncol.23, 190–196 (2005).
   PubMed Web of Science ®Google Scholar
• Neubauer MA, Reynolds CH, Joppert MG et al. Results of a Phase II trial of gemcitabine in patients with non-small-cell lung cancer and a performance status of 2. Clin. Lung Cancer6, 245–249 (2005).
   PubMedGoogle Scholar
• Gridelli C, Perrone F, Gallo C et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) Phase III randomized trial. J. Natl. Cancer Inst.95, 362–372 (2003).
   PubMed Web of Science ®Google Scholar
• Fossella FV, DeVore R, Kerr RN et al. Randomized Phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J. Clin. Oncol.18, 2354–2362 (2000).
   PubMed Web of Science ®Google Scholar
• Dipetrillo T, Milas L, Evans D et al. Paclitaxel poliglumex (PPX-Xyotax) and concurrent radiation for esophageal and gastric cancer: a Phase I study. Am. J. Clin. Oncol.29, 376–379 (2006).
   PubMed Web of Science ®Google Scholar
• Safran H, Akerman P, Cioffi W et al. Paclitaxel and concurrent radiation therapy for locally advanced adenocarcinomas of the pancreas, stomach, and gastroesophageal junction. Semin. Radiat. Oncol.9, 53–57 (1999).
   PubMed Web of Science ®Google Scholar
• Thatcher N, Chang A, Parikh P et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet366, 1527–1537 (2005).
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med.350, 2129–2139 (2004).
   PubMed Web of Science ®Google Scholar
• Cappuzzo F, Hirsch FR, Rossi E et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J. Natl. Cancer Inst.97, 643–655 (2005).
   PubMed Web of Science ®Google Scholar
• Olaussen KA, Dunant A, Fouret P et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N. Engl. J. Med.355, 983–991 (2006).
   PubMed Web of Science ®Google Scholar